|
1. BIOLOGIE
| |
|
|
1.4 BIOLOGIE - TECHNOS
| |
|
|
The Challenge of Using CRISPR to Knock In Genes [The Scientist]
| |
| | |
|
In the past few years, researchers have developed many new strategies to boost the efficiency of knocking in genes both large and small using CRISPR-Cas9, and along the way they’ve proposed and tested new applications for this type of gene editing. Here, The Scientist explores a few of the most promising approaches.
| |
| | |
|
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
| |
|
Radioactive cancer drugs could pose risk to cremation workers [Reuters]
| |
| | |
|
Yu and his colleagues were concerned that the heat from the cremation might have volatilized the radioactive drug, sending it into the air where it could be breathed in by anyone working at the crematorium. They contacted Arizona’s Board of Radiation Control, which sent out a team to measure any radioactivity in the crematorium that might be traced back to the patient.
| |
| | |
|
|
4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...
| |
|
|
4.12 BIOPSIES LIQUIDES
| |
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
| |
|
|
|
How to lead the world (in genomic healthcare) [PHG Foundation]
| |
|
| |
|
Maintaining a coordinated, coherent strategy across both sectors is an important step towards achieving this goal. However, there are many complexities that must be navigated to ensure a successful balance between health and wealth benefits from genomics, since they do not always align precisely.
| |
| | |
|
|
4.9 DÉP., DIAG. & PRONO. - SEIN
| |
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
| |
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
| |
|
|
5.2.1 PHARMA - PARTENARIATS
| |
|
J&J bags option on AdoRx lung cancer drugs [Fierce Biotech]
| |
| | |
|
AdoRx, a Scottish biotech, began operations in 2017 with a focus on discovering adenosine receptor antagonists that engage their targets in the adenosine-rich tumor microenvironment. That focus led AdoRx to embark on programs to discover drugs that block adenosine A2A or both A2A and A2B.
| |
| | |
|
|
5.2.2 PHARMA - FUSIONS & ACQUISITIONS
| |
|
Celgene Complications [In The Pipeline]
| |
| | |
|
And there’s always the outside chance that someone else will be convinced by those arguments and jump into the bidding as well. I don’t see that happening, but hey, Celgene is 8% cheaper today than it was yesterday, so it is arguably on sale.
| |
| | |
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
| |
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
| |
|
|
5.4 TRAITEMENTS - ECONOMIE
| |
|
|
5.9 AACR
| |
|
Amgen Highlights Progress Of Innovative Early Oncology Pipeline With New Data At AACR 2019 [Amgen]
| |
| | |
|
For the first time, preclinical data will be presented on AMG 510, a first-in-class investigational KRASG12C inhibitor being evaluated for the treatment of solid tumors. Data at the meeting will also showcase Amgen's novel bispecific T cell engager (BiTE®) platform, including preclinical data evaluating the use of AMG 757, a DLL3-targeted BiTE®molecule, in resistant subtypes of melanoma.
| |
| | |
|
|
6. LUTTE CONTRE LES CANCERS
| |
|
Cancer Trends Progress Report [NCI]
| |
| | |
|
The report, intended for policy makers, researchers, and public health professionals, includes key measures of progress along the cancer control continuum and uses national trend data to illustrate where improvements have been made.
| |
| | |
|
|
|
6.10 POLITIQUES
| |
|
|
6.6 PUBLICATIONS
| |
|
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
| |
|
|
6.9 CONTROVERSES
| |
|
|